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tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (tU) 
for 2 years or six courses of a 28-day cycle of doxorubicin 
40 mg/m2 plus cyclophosphamide 500 mg/m2 on day 1 
along with tamoxifen (aCt) given for 2 years as adjuvant 
therapy. Primary endpoint was overall survival (OS), and 
secondary endpoint was recurrence-free survival (rFS).
Results In total, 169 patients were recruited (tU arm 87, 
aCt arm 82) between October 1994 and September 1999. 
the Hr for OS was 0.76 (95 % CI 0.35, 1.66, log-rank 
p = 0.49) and that for rFS was 0.77 (95 % CI 0.44, 1.36, 
log-rank p = 0.37), with aCt resulting in a better Hr. the 
5-year OS was 79.7 % for patients in the tU arm and 83 % 
for those in the aCt arm. the 5-year rFS was 66.1 % for 
patients in the tU arm and 70.6 % for those in the aCt arm. 
a higher proportion of patients in the aCt arm experienced 
grade 3 leucopenia (0 % in the tU arm, 4 % in the aCt arm).
Conclusions there were no significant differences in the 
efficacy of tU and aCt as adjuvant therapy.
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Introduction
Progression-free survival and overall survival have been 
improved according to the development of postoperative 
adjuvant therapy using drugs based on clinical trials. Prior 
to the 1980s, cyclophosphamide, methotrexate, and fluoro-
uracil (CMF) therapy was the standard therapy, but devel-
opment of adriamycin in the 1990s indicated that adriamy-
cin might surpass CMF in terms of prolonging prognosis. 
Prior to the 1990s, oral anticancer agents became the stand-
ard therapy since they were thought to cause fewer adverse 
events in Japan.
Abstract 
Purpose a prospective randomized clinical trial was con-
ducted to evaluate the efficacy of tamoxifen plus doxoru-
bicin and cyclophosphamide compared to tamoxifen plus 
tegafur-uracil as an adjuvant therapy to treat node-positive 
premenopausal breast cancer (PreMBC).
Methods eligibility criteria included pathologically node-
positive (n = 1–9) preMBC with curative resection, in 
stages I–IIIa. Patients were randomized to receive either 
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Combined administration of oral fluoropyrimidine plus 
tamoxifen for 2 years postoperatively was reported to 
result in a high 5-year survival of 91 % for patients with 
Stage II breast cancer and 78 % for those with Stage III 
breast cancer [1, 2], and combined administration of oral 
fluoropyrimidine plus tamoxifen was reported to diminish 
QOl less [1]. the criteria for determination of estrogen 
receptor (er) status at the time differed from the current 
criteria, and tamoxifen was supposed to be less effica-
cious in er-negative patients. However, tamoxifen was 
administered regardless of the patient’s er status in gen-
eral. Moreover, the form of administration was typically 
in combination with an anticancer agent including chem-
otherapy and hormone therapy. this study was planned 
within this context.
Current postoperative drug therapy to treat breast can-
cer is often chosen depending on the breast cancer subtype, 
which is determined based on panels for markers such as 
er, Her2, and Ki67 [2]. this selection is based on pre-
dicted drug efficacy. the fact that lymph node metastasis 
is a prognostic factor was true when this trial began and 
it remains true today. When numerous lymph node metas-
tases are noted, standard therapy is the administration of 
anthracycline and taxane, regardless of the cancer subtype. 
this study sought to assess the superiority of adriamycin 
and cyclophosphamide (aC) + tamoxifen (aCt regimen) 
over oral tegafur-uracil (UFt) + tamoxifen (tU regimen), 
which was the standard therapy in Japan when the trial 
began, as a postoperative adjuvant therapy to treat premen-
opausal breast cancer in patients who were histopathologi-
cally confirmed to have lymph node metastasis. this trial 
also sought to determine whether all patients with node-
positive breast cancer needed to be administered anthra-
cycline or whether administration of oral fluoropyrimidine 
was sufficient.
Patients and methods
eligibility and excluding criteria
Premenopausal female patients over the age of 15 with 
Stage I–IIIa breast cancer were eligible for this study. 
all patients had to have undergone curative mastectomy 
with axillary node dissection, and a histological exami-
nation had to reveal involvement of 1–9 axillary nodes. 
Other eligibility criteria were a World Health Organiza-
tion (WHO) performance status of 0–1, adequate bone 
marrow and liver and kidney function, and no evidence 
of metastasis. Patients who received previous systemic 
treatment for breast cancer were excluded. the informed 
consent of each patient was obtained before study 
participation.
Planned treatment schedules
all patients randomized to tU or aCt regimen. For 
patients in the tU arm, tamoxifen (20 mg/day) and 
UFt (400 mg/day) were administered for a maximum 
of 2 years in all patients. For patients in the aCt arm, 
adriamycin (40 mg/m2 intravenously) and cyclophospha-
mide (500 mg/m2 intravenously) were administered on 
day 1 every 28 days. this cycle was repeated six times. 
tamoxifen (20 mg/day) was administered for a maximum 
of 2 years in all patients, regardless of hormonal receptor 
status.
randomization was done using the minimization 
method, and the arms were balanced with regard to er 
and progesterone receptor (Pr) status (either one positive 
(>10 %) versus both negative and unknown), Her2 status 
(positive versus negative or unknown), number of meta-
static nodes (1–3 versus 4–9), and institution.
Patient assessment
Initial workup included medical history, tumor assessment, 
physical examination, routine hematology and chemistry 
test, chest radiography, liver ultrasonography, and a bone 
scan. Hematology and chemistry tests, tumor marker meas-
urements, and urinalysis were repeated monthly. to check 
for distant metastasis, a chest radiography and liver ultra-
sonography were performed every 6 months, a bone scan 
was performed every year, and bilateral mammography was 
performed every 2 years. Hematological disorders and tox-
icity were evaluated according to the toxicity grading Cri-
teria of the Japan Clinical Oncology group (JCOg) [3] and 
were recorded on case report forms.
Study endpoint
the primary endpoint of this study was overall survival 
(OS), and the secondary endpoint was recurrence-free sur-
vival (rFS). OS was defined as the time from randomiza-
tion to death from any cause, and it was censored as of the 
date of final follow-up. rFS was defined as the time from 
randomization to either the first incidence of recurrence or 
death from any cause, and it was censored as of the date 
of final follow-up. OS and rFS were evaluated accord-
ing to hormone receptor status (either er- or Pr-positive 
versus both er- and Pr-negative or unknown) in sub-
group analyses. In addition, the safety of treatment was 
evaluated.
Statistical analysis plan
If patients treated with aCt had a significantly longer 
OS than patients treated with tU, then aCt would be 
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recommended as the new standard treatment. the estimated 
5-year OS of these patients is commonly 64–88 % [4–6]. 
a total of 342 patients were needed to detect a prolonga-
tion of the 5-year OS from 75 % for patients in the tU 
arm to 85 % for patients in aCt arm with an 80 % power 
and a two-sided alpha of 5 %. Considering some patients 
potentially lost to follow-up, the sample size was set at 400 
patients in total. the planned study period was originally 
2 years for recruitment and an additional 5 years for follow-
up. Due to the slow recruitment, the protocol was revised 
to extend the recruitment period, and the sample size was 
revised to 330 patients with a recruitment period of 5 years. 
OS was analyzed for all randomized patients and rFS for 
randomized patients excluding a patient with bone metasta-
sis at the registration. OS and rFS were estimated using the 
Kaplan–Meier method, and curves were compared using a 
log-rank test. Hazard ratios of treatment effects were esti-
mated by a Cox regression model. all analyses were based 
on intent to treat. all statistical analyses were performed 
using SaS release 8.2 (SaS Institute, Cary, nC).
Interim analysis and monitoring plan
an interim analysis was to be performed when half of the 
total number of patients was enrolled. the JCOg Data and 
Safety Monitoring Committee (DSMC) independently 
reviewed the interim analysis report, and premature ter-
mination of the trial could be considered at that stage. In-
house interim monitoring was performed by the JCOg Data 
Center to ensure data submission, patient eligibility, pro-
tocol compliance, safety, and on-schedule study progress. 
the monitoring reports were submitted to and reviewed by 
the DSMC every 6 months.
Results
this study began in 1994. at an interim analysis on June 
1999, patient recruitment was so slow that the DSMC rec-
ommended terminating patient recruitment or continuing but 
changing the primary endpoint to rFS. Furthermore, a con-
sensus meeting in St. gallen in 1997 deemed that administer-
ing tamoxifen to hormone receptor-negative patients was ethi-
cally unacceptable [7]. therefore, recruitment of patients was 
terminated pursuant to suggestions from the JCOg DSMC.
In total, 169 patients were recruited and randomly 
assigned (Fig. 1). Four patients were ineligible because 
two were enrolled after starting protocol treatment, one 
had been diagnosed with bone metastasis, and the other 
was postmenopausal before recruitment, but these patients 
were included in the analysis. the two groups had highly 
similar baseline characteristics (table 1). the median age 
was 46 years (30–56 years). One hundred and seventeen 
patients (69.2 %) had node metastases involving 1–3 
nodes, while 52 (30.8 %) had node metastases involving 
4–9 nodes. there were 59 patients (34.9 %) with er- or 
Pr-tumors, including patients with an unknown hormone 
status. Most patients (95.3 %) underwent total or radical 
mastectomy. eighty-seven patients were assigned to the 
tU arm, and 82 patients were assigned to the aCt arm. 
Patient’s diagram was shown in Fig. 1. the protocol treat-
ment in the tU arm was completed by 75 of 87 patients 
(86.2 %), and the protocol treatment in the aCt arm was 
completed by 66 of 82 patients (80.5 %).
Survival
there were no significant differences in OS for patients in 
the two arms (p = 0.494, hazard ratio 0.76, 95 % confi-
dence interval [CI] 0.35–1.66) (Fig. 2a). the 3- and 5-year 
OS were 90.3 and 79.7 % for patients in the tU arm and 
90.6 and 83.0 % for patients in the aCt arm, respectively. 
there were no significant differences in rFS for patients 
in the two arms (p = 0.37, Hr: 0.77, 95 % CI 0.44–1.36) 
(Fig. 2b). the 3- and 5-year rFS were 74.0 and 66.1 % for 
patients in the tU arm and 76.7 and 70.6 % for patients in 
the aCt arm, respectively.
Subgroup analysis was performed according to hormone 
receptor status. there were 57 patients (65.5 %) who were 
er+ and/or Pr+ in the tU arm and 52 (63.4 %) in the aCt 
arm. the OS curve is shown in Fig. 3a. Both er- and Pr-
negative patients had a worse prognosis than er-positive 
patients. However, patients in the tU and aCt arms had a 
similar OS, regardless of hormone status. Both er- and Pr-
negative patients in the tU arm had a relatively shorter rFS 
than those in the aCt arm (Fig. 3b). there were no differ-
ences in the rFS of er+ and/or Pr+ patients in both arms.
Safety profile
Safety profiles are listed in table 2a and B. Only one 
patient was observed grade 4 adverse event (gPt eleva-
tion) in the tU arm. this event was diagnosed at 35th day 
after the start of tU, and once the administration of UFt 
was halted, gPt decreased to normal levels. a higher pro-
portion of patients in the aCt arm had a lower white blood 
cell count that was rated grade 3 (0 % in the tU arm, 3.8 % 
in the aCt arm), and a higher proportion of patients in the 
tU arm had elevated total bilirubin, gOt, and gPt that 
were rated grade 3 (12.6, 2.3, and 2.3 % in the tU arm, 
0, 1.3, and 1.3 % in the aCt arm) and lower hemoglobin 
(3.4 % in the tU arm, 0 % in the aCt arm). a non-hemato-
logical toxicity (grade 3 nausea) was noted only in patients 
in the aCt arm (10 %). there was grade 3 rash (1.2 %) in 
a patient in the tU arm and grade 3 arrhythmia (1.3 %) in a 
patient in the aCt arm.
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Discussion
the decision to administer postoperative adjuvant drug 
therapy, which seeks to inhibit the recurrence of breast 
cancer, is often currently made based on the primary 
tumor’s subtype. Breast cancer is essentially categorized 
Fig. 1  trial profile of Japan 
Clinical Oncology group study, 
JCOg 9404
Table 1  Patient characteristics
Characteristics tU (n = 87) aCt (n = 82)
age (year)
 Median 47 45
 range 31–55 30–56
no. of positive axillary nodes
 1–3 59 58
 4–9 28 24
er and/or Pgr
 negative/unknown 29 30
 Positive 58 52
Her2
 negative/unknown 70 63
 Positive 17 19
Stage
 I 12 12
 II 58 60
 IIIa 17 11
Operation
 radical mastectomy 1 6
 total mastectomy 81 73
 Partial resection 5 3
Fig. 2  Kaplan–Meier curves of overall survival (a) and relapse-free 
survival (b) for node-positive breast cancer patients treated with 
tamoxifen plus tegafur-uracil or tamoxifen with anthracycline and 
cyclophosphamide
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into four subtypes depending on the expression of er, 
Pgr, Her2, and Ki67 [2]. endocrine drugs are given to 
patients with er- and/or Pgr-positive luminal tumors. 
trastuzumab (a molecular-targeted agent) and an antican-
cer agent are both administered to Her2-positive patients. 
these strategies are tailor-made target therapies accord-
ing to the prediction of efficacy of drugs. In addition to 
endocrine drugs, anticancer agents are often administered 
to patients with breast cancer expressing a high level of 
Ki67 [8, 9]. the individual determination of whether or 
not a tumor is sensitive to a drug is difficult, and despite 
this, anticancer agents are administered. Including anti-
cancer agents is considered acceptable when patients have 
numerous lymph node metastases (irrespective of tumor 
subtype), if their cancer is er- and/or Pgr-positive and 
expressing a low level of Ki67. the validity and evalua-
tion of Ki-67 are not definitive [10]. Both anthracycline 
and taxane are often administered sequentially for these 
patients despite the possibility that efficacy of these drugs 
is low. these classifications of breast cancer and adminis-
tration of taxane and molecular drugs were widely in use 
after the current trial began.
at the beginning of this study, tamoxifen was adminis-
tered as the standard therapy even if the patient was er-
negative. In light of current evidence, there is no doubt that 
tamoxifen has little efficacy in treating er-negative breast 
cancer [11], though there are also no data indicating that 
the efficacy of anticancer agents will diminish if used in 
combination with tamoxifen. thus, the results of this trial 
simply compared taking UFt for 2 years to taking aC to 
treat node-positive premenopausal breast cancer. Previous 
meta-analyses clearly revealed data indicating that aC ther-
apy is more effective at preventing recurrence than CMF 
[12–16], but aC therapy has not been compared to oral 
fluoropyrimidine. the results of this trial indicated no dif-
ference between oral fluoropyrimidine and aC therapy in 
terms of prolonging survival in patients overall. aC therapy 
resulted in a longer recurrence-free survival (rFS) in only 
er-negative patients. these results do not have a meaning 
Fig. 3  Kaplan–Meier curves of overall survival (a) and relapse-free 
survival (b) for node-positive breast cancer patients treated with 
tamoxifen plus tegafur-uracil or tamoxifen with anthracycline and 
cyclophosphamide according to estrogen receptor (er) and proges-
terone receptor (Pgr) status
Table 2  Hematological (a) and non-hematological (B) toxicities
toxicities grade 2 (%) grade 3 (%) grade 4 (%)
(a)
TU
 WBC 8 (9) 0 (0) 0 (0)
 Hb 2 (2) 3 (3) 0 (0)
 t-bill 43 (49) 11 (13) 0 (0)
 gOt 5 (6) 2 (2) 0 (0)
 gPt 9 (10) 2 (2) 1 (1)
ACT
 WBC 12 (14) 3 (3) 0 (0)
 Hb 7 (8) 0 (0) –
 t-bill 8 (9) 0 (0) 0 (0)
 gOt 1 (1) 1 (1) 0 (0)
 gPt 5 (6) 1 (1) 0 (0)
(B)
TU
 Infection 0 (0) 0 (0) 0 (0)
 nausea/vomiting 7 (0) 0 (0) –
 Diarrhea 2 (0) 0 (0) 0 (0)
 arrhythmia 1 (1) 0 (0) 0 (0)
 thrombosis 0 (0) 0 (0) 0 (0)
 alopecia 0 (0) – –
 rush 2 (0) 1 (0) 0 (0)
ACT
 Infection 0 (0) 0 (0) 0 (0)
 nausea/vomiting 29 (36) 8 (10) –
 Diarrhea 1 (1) 0 (0) 0 (0)
 arrhythmia 1 (1) 1 (1) 0 (0)
 thrombosis 0 (0) 0 (0) 0 (0)
 alopecia 37 (46) – –
 rush 1 (1) 0 (0) 0 (0)
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for recent breast cancer treatment strategy, because of the 
insufficiency of patients recruitment and old adjuvant treat-
ment design. However, this finding suggests that aC ther-
apy has limited efficacy when treating node-positive breast 
cancer by administering tamoxifen as a postoperative adju-
vant therapy to treat er-positive breast cancer. this finding 
also suggests that administration of oral fluoropyrimidine 
alone may be sufficient in some cases. In fact, OS and PFS 
were similar between aCt and tU arm with er-positive 
breast cancer. a potent anticancer agent, like anthracycline, 
may not be needed to treat er-positive breast cancer even 
if it has lymph node metastasis.
the question of whether UFt is needed or if tamoxifen 
alone is sufficient remains. results of the JCOg9401 study 
[17], which examined patients with postmenopausal breast 
cancer with lymph node metastasis during the same period 
as the current trial, may offer an answer. the study com-
pared tamoxifen alone and aCt therapy to treat patients 
with node-positive breast cancer, and results indicated that 
er-positive patients had a 5-year rFS of 59.3 % when 
given tamoxifen alone versus 76.9 % when given aCt 
therapy and a 5-year OS of 87.1 % when given tamoxifen 
alone versus 90 % when given aCt therapy. Patients in this 
trial who were given UFt+tamoxifen had a 5-year rFS 
of 74.5 % and a 5-year OS of 89 %. there was possibil-
ity of prognostic benefit of additional UFt for er-positive 
node-positive patients. thus, comparison of tU therapy to 
tamoxifen alone is needed. In Japan, a prospective clinical 
trial on adding S-1 to treat patients with er-positive breast 
cancer after completion of standard chemotherapy is cur-
rently enrolling subjects (UMIn000003969).
no major differences were noted in er-negative patients 
in either arm of this trial. that said, er-negative patients 
had a 5-year OS and a 5-year rFS that was about 30 % 
shorter than the 5-year OS and 5-year rFS of er-positive 
patients. trastuzumab tends to be administered to patients 
with er-negative breast cancer if they are Her2-positive 
[18], and taxane tends to be administered along with anthra-
cycline if they are Her2-negative [14]. the regimens in this 
trial were inadequate to evaluate the appropriate adjuvant 
drugs for er-negative patients with node metastases.
In terms of adverse events, a hematological event in the 
form of a grade 3 decline in the white blood cell count was 
noted only in patients in the aCt arm. In terms of non-
hematological events, abnormal liver function was noted 
in patients in the tU arm and nausea was often noted in 
patients in the aCt arm. results of this trial revealed 
numerous adverse events in patients in the aCt arm as a 
whole. Since the current dose of aC is higher than that used 
in this trial, UFt may be less damaging. However, results 
suggested that sufficient caution in abnormal liver function 
is necessary to use UFt for long time as adjuvant therapy. 
the current trial did not administer both endocrine therapy 
and chemotherapy concurrently. Previous data on such 
chemoendocrine therapy have highlighted the enhancement 
of adverse events and an increase in thrombosis in par-
ticular [19–21]. neither group of patients in this trial had 
thrombosis/embolism. existing data are from the USa and 
europe, where thrombosis is more prevalent. these condi-
tions may pose far less of a problem in Japan because of 
their different physique. Chemoendocrine therapy is ruled 
out based on current data from europe and the USa, but 
there may be leeway for therapy selection depending on the 
patient.
this trial prospectively studied the usefulness of aCt 
therapy to treat patients with node-positive premenopausal 
breast cancer. this trial began prior to 2000, and modern 
standard adjuvant therapy was established during collect-
ing patients for this trial. there were some issues with 
trial design and trial enrollment since the standard therapy 
changed substantially during trial enrollment. However, 
the times changed from an era of actively administering 
anticancer agents to every patient with breast cancer with 
lymph node metastasis to an era of selecting therapy by 
predicting drug efficacy. Postoperative adjuvant therapy 
with oral FU was the standard therapy in this trial, and a 
new appreciation for the efficacy of that therapy is develop-
ing. In this trial, aCt did not significantly prolong survival 
compared to tUFt, especially in er-positive patients. 
Without a doubt, these findings pose clinical questions that 
should be answered when formulating a treatment strategy 
for postoperative adjuvant therapy. Further studies via pro-
spective trials (which include those currently underway) 
are needed.
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